Co-Diagnostics Capital Expenditures (CapEx) Growth & History (CODX)
Co-Diagnostics's capital expenditures (capex) was $700,047 for fiscal 2025.
View full Co-Diagnostics company overviewCo-Diagnostics annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $700,047 | −$48,305 | −6.45% |
| 2024 | 2024-12-31 | $748,352 | −$616,954 | −45.19% |
| 2023 | 2023-12-31 | $1.4M | −$62,206 | −4.36% |
| 2022 | 2022-12-31 | $1.4M | $758,049 | +113.23% |
| 2021 | 2021-12-31 | $669,463 | −$104,934 | −13.55% |
| 2020 | 2020-12-31 | $774,397 | $661,151 | +583.82% |
| 2019 | 2019-12-31 | $113,246 | $71,910 | +173.96% |
| 2018 | 2018-12-31 | $41,336 | −$87,970 | −68.03% |
| 2017 | 2017-12-31 | $129,306 | $117,065 | +956.34% |
| 2016 | 2016-12-31 | $12,241 | — | — |
Co-Diagnostics quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $18,281 | −$382,779 | −95.44% |
| Q1 2026 | 2026-03-31 | $142,017 | $50,104 | +54.51% |
| Q4 2025 | 2025-12-31 | $131,969 | $58,982 | +80.81% |
| Q3 2025 | 2025-09-30 | $75,105 | −$99,338 | −56.95% |
| Q2 2025 | 2025-06-30 | $401,060 | $302,431 | +306.63% |
| Q1 2025 | 2025-03-31 | $91,913 | −$310,380 | −77.15% |
| Q4 2024 | 2024-12-31 | $72,987 | −$391,615 | −84.29% |
| Q3 2024 | 2024-09-30 | $174,443 | −$62,124 | −26.26% |
| Q2 2024 | 2024-06-30 | $98,629 | −$385,564 | −79.63% |
| Q1 2024 | 2024-03-31 | $402,293 | $222,349 | +123.57% |
| Q4 2023 | 2023-12-31 | $464,602 | $171,298 | +58.40% |
| Q3 2023 | 2023-09-30 | $236,567 | $6,519 | +2.83% |
| Q2 2023 | 2023-06-30 | $484,193 | −$23,367 | −4.60% |
| Q1 2023 | 2023-03-31 | $179,944 | −$216,656 | −54.63% |
| Q4 2022 | 2022-12-31 | $293,304 | $171,549 | +140.90% |
| Q3 2022 | 2022-09-30 | $230,048 | $64,321 | +38.81% |
| Q2 2022 | 2022-06-30 | $507,560 | $265,137 | +109.37% |
| Q1 2022 | 2022-03-31 | $396,600 | $257,042 | +184.18% |
| Q4 2021 | 2021-12-31 | $121,755 | −$346,959 | −74.02% |
| Q3 2021 | 2021-09-30 | $165,727 | $65,334 | +65.08% |
| Q2 2021 | 2021-06-30 | $242,423 | $137,503 | +131.06% |
| Q1 2021 | 2021-03-31 | $139,558 | $39,188 | +39.04% |
| Q4 2020 | 2020-12-31 | $468,714 | — | — |
| Q3 2020 | 2020-09-30 | $100,393 | $76,142 | +313.97% |
| Q2 2020 | 2020-06-30 | $104,920 | — | — |
| Q1 2020 | 2020-03-31 | $100,370 | — | — |
| Q3 2019 | 2019-09-30 | $24,251 | $17,062 | +237.33% |
| Q4 2018 | 2018-12-31 | $38,836 | $488 | +1.27% |
| Q3 2018 | 2018-09-30 | $7,189 | $3,837 | +114.47% |
| Q2 2018 | 2018-06-30 | $1 | −$46,559 | −100.00% |
| Q1 2018 | 2018-03-31 | $9,688 | −$31,358 | −76.40% |
| Q4 2017 | 2017-12-31 | $38,348 | — | — |
| Q3 2017 | 2017-09-30 | $3,352 | $3,352 | — |
| Q2 2017 | 2017-06-30 | $46,560 | — | — |
| Q1 2017 | 2017-03-31 | $41,046 | — | — |
| Q3 2016 | 2016-09-30 | $0 | — | — |
Co-Diagnostics capital expenditures (capex) trends
Over the last five fiscal years, Co-Diagnostics's capital expenditures (capex) decreased from $774,397 to $700,047, a change of −$74,350. The latest reported quarter, Q2 2026, shows $18,281.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Co-Diagnostics source filings ↗